N-[3-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6,7-dihydropyrrolo[3,4-g]quinolin-5-yl]-N-methylmethanesulfonamide | 959402-90-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[3-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6,7-dihydropyrrolo[3,4-g]quinolin-5-yl]-N-methylmethanesulfonamide
• CAS: 959402-90-5
• 化学式: C₂₀H₁₈FN₃O₄S
• 分子量: 415.445
• InChiKey: TYHFGXXLBDNCAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[3-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6,7-dihydropyrrolo[3,4-g]quinolin-5-yl]-N-methylmethanesulfonamide 、 4-甲氧基溴苄 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[3-[(4-fluorophenyl)methyl]-9-[(4-methoxyphenyl)methoxy]-8-oxo-6,7-dihydropyrrolo[3,4-g]quinolin-5-yl]-N-methylmethanesulfonamide
  参考文献：
  名称：

  Tricyclic HIV integrase inhibitors: VI. SAR studies of ‘benzyl flipped’ C3-substituted pyrroloquinolines

  摘要：

  A series of C3 halobenzyl-substituted tricyclic HIV integrase inhibitors was prepared. Improvement in cell-based inhibitor potency was observed in comparison to previously disclosed tricyclic pyrroloquinolines carrying the 'halobenzyl tail' at the lactam nitrogen. Animal PK for several of the C3-substituted inhibitors was examined, with a dihaloaryl analog achieving good balance in protein-shifted EC50 and t(1/2) in animal PK studies. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.079
• 作为产物：
  描述：

  在 2-[[三(羟甲基)甲基]氨基]乙磺酸 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 N-[3-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6,7-dihydropyrrolo[3,4-g]quinolin-5-yl]-N-methylmethanesulfonamide
  参考文献：
  名称：

  Tricyclic HIV integrase inhibitors: VI. SAR studies of ‘benzyl flipped’ C3-substituted pyrroloquinolines

  摘要：

  A series of C3 halobenzyl-substituted tricyclic HIV integrase inhibitors was prepared. Improvement in cell-based inhibitor potency was observed in comparison to previously disclosed tricyclic pyrroloquinolines carrying the 'halobenzyl tail' at the lactam nitrogen. Animal PK for several of the C3-substituted inhibitors was examined, with a dihaloaryl analog achieving good balance in protein-shifted EC50 and t(1/2) in animal PK studies. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.079

文献信息

• Integrase inhibitors
  申请人：Cai R. Zhenhong

  公开号：US20080058315A1

  公开（公告）日：2008-03-06

  Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  三环化合物，其受保护的中间体，以及用于抑制HIV整合酶的方法被披露。
• INTEGRASE INHIBITORS
  申请人：Cai Zhenhong R.

  公开号：US20090306054A1

  公开（公告）日：2009-12-10

  Tricyclic compounds of formulae I-III, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
• US8008287B2
  申请人：——

  公开号：US8008287B2

  公开（公告）日：2011-08-30
• [EN] INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS D'INTÉGRASE
  申请人：GILEAD SCIENCES INC

  公开号：WO2007136714A2

  公开（公告）日：2007-11-29

  [EN] Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
  [FR] L'invention concerne des composés tricycliques, des intermédiaires protégés de ceux-ci, ainsi que des méthodes d'inhibition de l'intégrase du VIH.
• Tricyclic HIV integrase inhibitors: VI. SAR studies of ‘benzyl flipped’ C3-substituted pyrroloquinolines
  作者：Sammy Metobo、Michael Mish、Haolun Jin、Salman Jabri、Rachael Lansdown、Xiaowu Chen、Manuel Tsiang、Matthew Wright、Choung U. Kim

  DOI：10.1016/j.bmcl.2008.12.079

  日期：2009.2

  A series of C3 halobenzyl-substituted tricyclic HIV integrase inhibitors was prepared. Improvement in cell-based inhibitor potency was observed in comparison to previously disclosed tricyclic pyrroloquinolines carrying the 'halobenzyl tail' at the lactam nitrogen. Animal PK for several of the C3-substituted inhibitors was examined, with a dihaloaryl analog achieving good balance in protein-shifted EC50 and t(1/2) in animal PK studies. (C) 2008 Elsevier Ltd. All rights reserved.